Identification
Name2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine
Accession NumberDB02104  (EXPT00976)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 384.4323
Monoisotopic: 384.190988664
Chemical FormulaC19H24N6O3
InChI KeyPEGMMEYCSOZKIT-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N6O3/c1-10-11(8-22-18-15(10)17(20)23-19(21)24-18)9-25(2)12-6-13(26-3)16(28-5)14(7-12)27-4/h6-8H,9H2,1-5H3,(H4,20,21,22,23,24)
IUPAC Name
5-methyl-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}pyrido[2,3-d]pyrimidine-2,4-diamine
SMILES
COC1=CC(=CC(OC)=C1OC)N(C)CC1=C(C)C2=C(N)N=C(N)N=C2N=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Dihydrofolate reductaseProteinunknownNot AvailableHumanP00374 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP2.2ALOGPS
logP2.02ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)16.06ChemAxon
pKa (Strongest Basic)3.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.64 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity111.35 m3·mol-1ChemAxon
Polarizability41.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9377
Caco-2 permeable+0.6435
P-glycoprotein substrateSubstrate0.679
P-glycoprotein inhibitor INon-inhibitor0.529
P-glycoprotein inhibitor IINon-inhibitor0.5612
Renal organic cation transporterNon-inhibitor0.7585
CYP450 2C9 substrateNon-substrate0.8777
CYP450 2D6 substrateNon-substrate0.868
CYP450 3A4 substrateSubstrate0.5439
CYP450 1A2 substrateNon-inhibitor0.5735
CYP450 2C9 inhibitorNon-inhibitor0.6933
CYP450 2D6 inhibitorNon-inhibitor0.577
CYP450 2C19 inhibitorNon-inhibitor0.6567
CYP450 3A4 inhibitorNon-inhibitor0.8495
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.646
Ames testNon AMES toxic0.5899
CarcinogenicityNon-carcinogens0.9025
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4154 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8731
hERG inhibition (predictor II)Non-inhibitor0.5888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassPyridopyrimidines
Direct ParentPyrido[2,3-d]pyrimidines
Alternative ParentsAminophenyl ethers / Methoxyanilines / Phenoxy compounds / Anisoles / Dialkylarylamines / Methoxybenzenes / Alkyl aryl ethers / Aminopyrimidines and derivatives / Aralkylamines / Methylpyridines
SubstituentsPyrido[2,3-d]pyrimidine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Dialkylarylamine / Anisole / Aniline or substituted anilines / Phenol ether / Methoxybenzene
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorspyridopyrimidine (CHEBI:41589 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 17:06